UBS raised the firm’s price target on AstraZeneca to 10,500 GBp from 9,900 GBp and keeps a Sell rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- 3 Best Healthcare Stocks to Buy in April 2024, According to Analysts
- AstraZeneca’s Q1 2024: Revenue and Dividend Leap
- AstraZeneca backs FY24 core EPS view up low double-digit to low teens percentage
- AstraZeneca reports Q1 core EPS $2.06, consensus $1.22
- AZN Earnings: AstraZeneca Soars on Impressive Q1 Results
